Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2. (Q43621538)

25 November 2017

Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2. (English)

1 reference

25 November 2017

Cockerill S

1

1 reference

25 November 2017

Stubberfield C

2

1 reference

25 November 2017

Stables J

3

1 reference

25 November 2017

Carter M

4

1 reference

25 November 2017

Guntrip S

5

1 reference

25 November 2017

Smith K

6

1 reference

25 November 2017

McKeown S

7

1 reference

25 November 2017

Shaw R

8

1 reference

25 November 2017

Topley P

9

1 reference

25 November 2017

Thomsen L

10

1 reference

25 November 2017

Affleck K

11

1 reference

25 November 2017

Jowett A

12

1 reference

25 November 2017

Hayes D

13

1 reference

25 November 2017

Willson M

14

1 reference

25 November 2017

Woollard P

15

1 reference

25 November 2017

Spalding D

16

1 reference

25 November 2017

language of work or name

English

0 references

publication date

1 June 2001

1 reference

25 November 2017

5

1 reference

Bioorganic & Medicinal Chemistry Letters

inferred from page(s)

published in

1 reference

25 November 2017

11

1 reference

25 November 2017

11

1 reference

25 November 2017

1401-1405

1 reference

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

25 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900219-0

7 January 2021

Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900219-0

7 January 2021

Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900219-0

7 January 2021

Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900219-0

7 January 2021

Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900219-0

7 January 2021

Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900219-0

7 January 2021

ErbB receptor activation, cell morphology changes, and apoptosis induced by anti-Her2 monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2801%2900219-0

7 January 2021

10.1016/S0960-894X(01)00219-0

Identifiers

DOI

1 reference

25 November 2017

1 reference